Tharimmune (NASDAQ:THAR) Trading Down 3.2%

Tharimmune, Inc. (NASDAQ:THARGet Free Report) shares traded down 3.2% during trading on Wednesday . The stock traded as low as $0.37 and last traded at $0.38. 216,216 shares were traded during mid-day trading, a decline of 66% from the average session volume of 635,400 shares. The stock had previously closed at $0.39.

Tharimmune Price Performance

The stock has a fifty day simple moving average of $0.51. The stock has a market capitalization of $263,900.00, a price-to-earnings ratio of -0.02 and a beta of 1.62.

Tharimmune (NASDAQ:THARGet Free Report) last announced its quarterly earnings data on Tuesday, November 7th. The company reported ($2.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.25) by ($1.50). On average, sell-side analysts expect that Tharimmune, Inc. will post -0.54 EPS for the current year.

Tharimmune Company Profile

(Get Free Report)

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).

Featured Stories

Receive News & Ratings for Tharimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tharimmune and related companies with MarketBeat.com's FREE daily email newsletter.